Dr Alison Birtle is a Consultant Clinical Oncologist based at The Rosemere Cancer Centre, Preston.

Dr Birtle’s specialist interests cover chemotherapy for urological tumours, targeted therapy and radiotherapy developments. She trained in London at Charing Cross and Westminister Medical School and as a specialist registrar in clinical oncology in North Thames. She  completed her MD Thesis at the Institute of Urology, University College London, in PSA negative prostate cancer and finished site specialised training at the  Academic Urology Unit, Royal Marsden Hospital.

In November 2007, Dr Birtle was appointed ‘Honorary Clinical Senior Lecturer’ at The University of Manchester in recognition of her academic and clinical research of cancer.

She was Clinical Lead for Research for Lancs & South Cumbria Cancer Research Network until April 2014 and is a member of the Research and innovation Committee at Lancs Teaching Hospitals NHS Foundation Trust and an active member of the Cancer Research Partnership Group.

Dr Birtle is committee member of the British Uro-Oncology Group and Trustee of the Action on Bladder cancer.